Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. (Record no. 26115002)

MARC details
000 -LEADER
fixed length control field 01578 a2200397 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250517101349.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201705s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1942-5546
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1016/j.mayocp.2016.02.023
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Nassan, Malik
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20170524
245 00 - TITLE STATEMENT
Title Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Mayo Clinic proceedings
Date of publication, distribution, etc. 07 2016
300 ## - PHYSICAL DESCRIPTION
Extent 897-907 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Journal Article; Review; Research Support, N.I.H., Extramural
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antidepressive Agents, Second-Generation
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cytochrome P-450 CYP2D6
General subdivision genetics
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cytochrome P-450 Enzyme Inhibitors
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Depressive Disorder, Major
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Fluoxetine
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Paroxetine
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pharmacogenetics
General subdivision methods
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Practice Guidelines as Topic
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Precision Medicine
General subdivision methods
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Prescription Drugs
General subdivision standards
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Venlafaxine Hydrochloride
General subdivision adverse effects
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Nicholson, Wayne T
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Elliott, Michelle A
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Rohrer Vitek, Carolyn R
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Black, John L
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Frye, Mark A
773 0# - HOST ITEM ENTRY
Title Mayo Clinic proceedings
Related parts vol. 91
-- no. 7
-- p. 897-907
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1016/j.mayocp.2016.02.023">https://doi.org/10.1016/j.mayocp.2016.02.023</a>
Public note Available from publisher's website

No items available.